Zealth is specialized in market access and HTA submissions in the Nordics.
We help healthcare companies bring their products to patients by focusing on healthcare ― and on building demand and overcome market barriers. We are proud of our company values and keep ourselves accountable to live our values of
‘customer satisfaction through execution and delivering on commitments’.
We always put our customers first.
We provide a wide range of solutions, from helping with Medical affairs, Medical education, national and regional Market access projects and strategies to submission of full HTAs to local authorities in the Nordics. We also take on tasks such as performance and management presentations for your leadership team, where a fast turnaround is key. We have developed numerous mapping projects, playbooks, and internal training materials, prepared medical reference packages, and performed quality reviews. Furthermore, we have extensive experience within the healthcare bodies and stakeholders in the Nordics.
To gain market access and successful HTA submissions in the Nordics, it is essential to understand every stakeholder and how they are involved in the access decision. Ultimately, the payer needs to see the unmet medical need and acknowledge the value that your product brings. To be successful, payers should be willing to both pay for and include your product as standard treatment. We can help you understand the HTA systems and develop a strategy that addresses every stakeholder and meets their specific needs for data, knowledge, and collaboration.
At Zealth, we always start by identifying and analyzing market access barriers. Every barrier needs to be identified and resolved. Being unsuccessful in eliminating these barriers will in most cases result in restricted or no access. Since it is essential to communicate with many different types of stakeholders, taking an interdisciplinary approach is crucial in ensuring market access.
HTA submissions in the Nordics
A crucial factor in the payer decision framework is the cost-effectiveness of drug therapies, which implies that the cost of a drug must be acceptable when considering the benefits provided. Therefore, determining appropriate price levels―resulting in acceptable cost-effectiveness ratios―is essential in gaining market access and successful HTA submissions in the countries of Denmark, Sweden, Norway and Finland. In addition, forming payer partnerships is important in ensuring that product sales and value are balanced.
Our goal is to help bring new drugs to patients as fast as possible, thereby facilitating patient and market access. We believe that by supporting companies, ensuring clear communication, and providing the right data to the decision makers, the process can run more smoothly, and new drugs and/or new indications can be approved faster.
We know the importance of communicating clear and correct content to healthcare professionals in the Nordics, since their capacity and time to absorb new information is limited. With our extensive background within medicine and pharmaceutical sciences, we offer services focusing on medical communications and medical affairs, which helps our customers frame their product propositions in a way that healthcare professionals in the Nordics find relevant and useful.